Correction to: Neuropsychopharmacology (2015) 40, 2025–2037; doi:10.1038/npp.2015.52; published online 1 April 2015

Following publication, the authors reported the following errors in Figure 2, Table 2, and Supplementary Appendixes A–C. These small errors do not change the content, statistics, or conclusions of the report.

Figure 2
figure 1

PowerPoint slide

Full size image

Page 2030: In Figure 2, the label below the x axis should say that the mean DSST score was 43.1, not 42.

Page 2031, Table 2:

In the top row (‘DSST-number of correct symbols’), the upper CI limit for duloxetine is incorrect. The entry should read ‘1.21±0.73 (−0.23; 2.65)’, not ‘1.21±0.73 (−0.23; 2.56)’.

Under ‘Secondary end points assessing cognitive dysfunction,’ in the row ‘Identification task,’ the difference from placebo for vortioxetine should be −0.01, not −0.02.

Under ‘Additional endpoints’, in the row ‘WLQ–Percentage Productivity Loss’, the change from baseline for placebo should be −3.07±0.65, not 3.07±0.65. In the row ‘WLQ–Time Management’, the change from baseline for placebo should be −12.78±3.02, not −3.07±0.65.

Supplementary Appendix A online: The screening period was from Day -10 to Day -2, not Day -14 to Day -7.

Supplementary Appendix B online: Under ‘Additional Endpoints’, in the fourth item, the name of the university and the description of the measure are incorrect. The entry should be ‘Change from baseline to week 8 in the University of California San Diego Performance-Based Skills Assessment (UPSA) (performance-based measure of functional capacity)’, not ‘Change from baseline to week 8 in the University of San Diego Performance-Based Skills Assessment (UPSA) (performance measures of functional capacity)’.

Supplementary Appendix C online: Some asterisks were difficult to interpret, and the n value for duloxetine at 4 weeks was incorrect. Please see the corrected graph accompanying the corrigendum, below and online.